Neurosense Therapeutics is trading 5% up in after-hours trading at $0.40 after the August 18, 2026 close of $0.38, reflecting limited positioning rather than a confirmed catalyst.
- Regular-session decline: 11.57%; no fresh company-specific announcement on August 18.
- U.S.-Iran tensions lifted oil prices and Treasury yields, pressuring growth-oriented assets and technology stocks; Reuters: 30-year yield highest since 2007.
- August 26 shareholder meeting, including potential reverse-split authorization, remains a risk; announced earlier, it does not clearly explain the August 18 move.